Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
15-Sep-2026 | 968 | 968.75 | 902.25 | 911.9 | 35,157 | 70,36,81,334.6 | 3,23,705 |
16-Sep-2026 | 909.9 | 945 | 874.85 | 928.05 | 51,170 | 1,08,18,03,973.6 | 4,38,907 |
17-Sep-2026 | 923 | 963 | 923 | 958.35 | 38,709 | 78,06,32,241.75 | 3,97,903 |
18-Sep-2026 | 958.35 | 1,033.1 | 951.9 | 1,021.1 | 64,447 | 1,76,99,89,511 | 6,09,436 |
21-Sep-2026 | 1,021.1 | 1,075 | 1,017.6 | 1,070.8 | 58,733 | 1,55,62,52,467.9 | 4,84,530 |
22-Sep-2026 | 1,060 | 1,073 | 1,023.3 | 1,033.15 | 31,921 | 70,85,49,710.4 | 2,58,024 |
23-Sep-2026 | 1,040 | 1,054 | 1,010 | 1,037.7 | 37,996 | 63,49,08,215.5 | 2,28,313 |
24-Sep-2026 | 1,035.8 | 1,055 | 992 | 1,007.3 | 34,408 | 63,79,47,169.55 | 2,63,490 |
25-Sep-2026 | 1,028 | 1,045.55 | 1,001.5 | 1,013.45 | 33,897 | 61,73,14,002.05 | 1,96,023 |
28-Sep-2026 | 1,018 | 1,039 | 998 | 1,025.25 | 33,055 | 69,15,52,606.2 | 2,78,356 |
29-Sep-2026 | 1,033.1 | 1,071.1 | 1,018.7 | 1,055.75 | 52,315 | 91,64,14,011.7 | 3,38,416 |
30-Sep-2026 | 1,060 | 1,075 | 1,033.5 | 1,047.2 | 32,209 | 51,87,88,422.3 | 2,11,704 |
01-Oct-2026 | 1,044 | 1,095 | 1,034.6 | 1,064.1 | 75,167 | 1,81,56,23,482.7 | 5,94,819 |
05-Oct-2026 | 1,069 | 1,081.9 | 1,020.2 | 1,031.2 | 35,667 | 90,70,47,337.2 | 5,71,626 |
06-Oct-2026 | 1,028.1 | 1,079.9 | 1,026.1 | 1,073.7 | 35,352 | 62,34,16,086.8 | 2,79,396 |
07-Oct-2026 | 1,072.4 | 1,086.8 | 1,055.1 | 1,071.2 | 27,531 | 46,35,22,217 | 2,01,944 |
08-Oct-2026 | 1,077.5 | 1,077.5 | 1,016 | 1,025.3 | 38,636 | 69,84,32,572.5 | 3,60,223 |
09-Oct-2026 | 1,025.4 | 1,048.2 | 991.4 | 1,021.7 | 27,604 | 40,46,67,935.5 | 1,61,598 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
